Ysios Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Memo Therapeuticsmemo-therapeutics.cominMay 2024acquired by Clementia
Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer.
BiotechMedical Devices
Co-investorsAdjuvant CapitalFresenius Medical Care VenturesKurma PartnersPureos BioventuresVerve Venturesredalpine
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.